The FDA is expected to take another look at controversial diabetes drug Avandia after researchers at Duke have concluded the drug doesn't increase the risk of cardiovascular death as previously reported.
The FDA is expected to take another look at controversial diabetes drug Avandia after researchers at Duke have concluded the drug doesn't increase the risk of cardiovascular death as previously reported. - 
Listen To The Story
Marketplace

The FDA is expected to take another look at controversial diabetes drug Avandia after researchers at Duke have concluded the drug doesn't increase the risk of cardiovascular death as previously reported. But is it too little too late?

Shelter magazines are on the rebound as the housing industry bounces back. What other lateral signs are there out there?

Stocks are risky, but bonds are safe, or so goes the stereotype. Buy a solid bond -- the logic goes -- and you get your money back at maturity with interest. Then there are bond mutual funds, which are built on bonds, but are a very different animal than straight up bonds. As interest rates have risen over the past month, dividends for some of the nation's largest bond funds have been all but wiped out.

“I think the best compliment I can give is not to say how much your programs have taught me (a ton), but how much Marketplace has motivated me to go out and teach myself.” – Michael in Arlington, VA

As a nonprofit news organization, what matters to us is the same thing that matters to you: being a source for trustworthy, independent news that makes people smarter about business and the economy. So if Marketplace has helped you understand the economy better, make more informed financial decisions or just encouraged you to think differently, we’re asking you to give a little something back.

Become a Marketplace Investor today – in whatever amount is right for you – and keep public service journalism strong. We’re grateful for your support.

Follow David Brancaccio at @DavidBrancaccio